Related references
Note: Only part of the references are listed.The 2021 WHO Classification of Tumors of the Central Nervous System: a summary
David N. Louis et al.
NEURO-ONCOLOGY (2021)
A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01)
Carmen Balana et al.
NEURO-ONCOLOGY (2020)
Clinical Efficacy of Tumor Treating Fields for Newly Diagnosed Glioblastoma
Yang Liu et al.
ANTICANCER RESEARCH (2020)
The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma multiforme: a meta-analysis and systematic review
Ehsan Alimohammadi et al.
ONCOLOGY REVIEWS (2020)
Temozolomide Induced Hypermutation in Glioma: Evolutionary Mechanisms and Therapeutic Opportunities
Paul Daniel et al.
FRONTIERS IN ONCOLOGY (2019)
Super-early initiation of temozolomide prolongs the survival of glioblastoma patients without gross-total resection: a retrospective cohort study
Haihui Jiang et al.
JOURNAL OF NEURO-ONCOLOGY (2019)
Australian Utility Weights for the EORTC QLU-C10D, a Multi-Attribute Utility Instrument Derived from the Cancer-Specific Quality of Life Questionnaire, EORTC QLQ-C30
Madeleine T. King et al.
PHARMACOECONOMICS (2018)
Early postsurgical temozolomide treatment in newly diagnosed bad prognosis glioblastoma patients: Feasibility study
Elly Chaskis et al.
BULLETIN DU CANCER (2018)
A Phase 2 Trial of Neoadjuvant Temozolomide (TMZ) Followed By Accelerated Hypofractionated Radiation Therapy (AHRT) and TMZ Followed By Adjuvant TMZ in Patients with Newly Diagnosed Glioblastoma (GBM): Long Term Survival and Toxicity Analysis
G. Shenouda et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2018)
Efficacy and safety results of ABT-414 in combination with radiation and temozolomide in newly diagnosed glioblastoma
David A. Reardon et al.
NEURO-ONCOLOGY (2017)
A Phase 2 Trial of Neoadjuvant Temozolomide Followed by Hypofractionated Accelerated Radiation Therapy With Concurrent and Adjuvant Temozolomide for Patients With Glioblastoma
George Shenouda et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2017)
Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG
Deborah T. Blumenthal et al.
NEURO-ONCOLOGY (2017)
Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials
Benjamin M. Ellingson et al.
NEUROTHERAPEUTICS (2017)
Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma
James R. Perry et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy
N. D. James et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Early versus delayed initiation of adjuvant treatment for pancreatic cancer
Hyoung Woo Kim et al.
PLOS ONE (2017)
Genetic Evolution of Glioblastoma Stem-Like Cells From Primary to Recurrent Tumor
Francesca Orzan et al.
STEM CELLS (2017)
Efficacy and safety of long-term therapy for high-grade glioma with temozolomide: A meta-analysis
Weilin Xu et al.
ONCOTARGET (2017)
Postoperative neoadjuvant temozolomide before radiotherapy versus standard radiotherapy in patients 60 years or younger with anaplastic astrocytoma or glioblastoma: a randomized trial
Annika Malmstrom et al.
ACTA ONCOLOGICA (2017)
Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future
Nicholas McGranahan et al.
CELL (2017)
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2016)
Temozolomide resistance in glioblastoma multiforme
Sang Y. Lee
GENES & DISEASES (2016)
Does Early Postsurgical Temozolomide Plus Concomitant Radiochemotherapy Regimen Have Any Benefit in Newly-diagnosed Glioblastoma Patients A Multi-center, Randomized, Parallel, Open-label, Phase II Clinical Trial
Ying Mao et al.
CHINESE MEDICAL JOURNAL (2015)
Growth dynamics of untreated glioblastomas in vivo
Anne Line Stensjoen et al.
NEURO-ONCOLOGY (2015)
Should we continue temozolomide beyond six cycles in the adjuvant treatment of glioblastoma without an evidence of clinical benefit? A cost analysis based on prescribing patterns in Spain
C. Balana et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2014)
AN AUSTRALIAN DISCRETE CHOICE EXPERIMENT TO VALUE EQ-5D HEALTH STATES
Rosalie Viney et al.
HEALTH ECONOMICS (2014)
Time to Initiation of Adjuvant Chemotherapy for Early Breast Cancer and Outcome: The Earlier, the Better?
Marco Colleoni et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Temporal relationship of post-operative radiotherapy with temozolomide and oncologic outcome for glioblastoma
Daniel E. Spratt et al.
JOURNAL OF NEURO-ONCOLOGY (2014)
Prognostic impact of the time interval between surgery and chemotherapy in advanced ovarian cancer: Analysis of prospective randomised phase III trials
S. Mahner et al.
EUROPEAN JOURNAL OF CANCER (2013)
O6-methylguanine DNA methyltransferase as a promising target for the treatment of temozolomide-resistant gliomas
C-H Fan et al.
CELL DEATH & DISEASE (2013)
Temozolomide Dosing Regimens for Glioma Patients
Herwig M. Strik et al.
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS (2012)
NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: A randomised phase III trial of a novel treatment modality
Roger Stupp et al.
EUROPEAN JOURNAL OF CANCER (2012)
Flexible trial design in practice - stopping arms for lack-of-benefit and adding research arms mid-trial in STAMPEDE: a multi-arm multi-stage randomized controlled trial
Matthew R. Sydes et al.
TRIALS (2012)
Tumor regrowth between surgery and initiation of adjuvant therapy in patients with newly diagnosed glioblastoma
Andrea Pirzkall et al.
NEURO-ONCOLOGY (2009)
STAMPEDE: Systemic Therapy for Advancing or Metastatic Prostate Cancer - A multi-arm multi-stage randomised controlled trial
N. D. James et al.
CLINICAL ONCOLOGY (2008)
Survival in high-grade glioma: A study of survival in patients unfit for or declining radiotherapy
RJ Prestwich et al.
CLINICAL ONCOLOGY (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
The effect of waiting for radiotherapy for grade III/IV gliomas
V Do et al.
RADIOTHERAPY AND ONCOLOGY (2000)